0001209191-23-046639.txt : 20230818
0001209191-23-046639.hdr.sgml : 20230818
20230818183108
ACCESSION NUMBER: 0001209191-23-046639
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230816
FILED AS OF DATE: 20230818
DATE AS OF CHANGE: 20230818
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ali Faraz
CENTRAL INDEX KEY: 0001667937
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40656
FILM NUMBER: 231186937
MAIL ADDRESS:
STREET 1: C/O TENAYA THERAPEUTICS, INC.
STREET 2: 171 OYSTER POINT BLVD., 5TH FLR.
CITY: SOUTH SAN FRANCISCO
STATE: Z4
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Tenaya Therapeutics, Inc.
CENTRAL INDEX KEY: 0001858848
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 813789973
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 171 OYSTER POINT BLVD., SUITE 500
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 415-865-2066
MAIL ADDRESS:
STREET 1: 171 OYSTER POINT BLVD., SUITE 500
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-08-16
0
0001858848
Tenaya Therapeutics, Inc.
TNYA
0001667937
Ali Faraz
C/O TENAYA THERAPEUTICS, INC.
171 OYSTER POINT BLVD., 5TH FLOOR
SOUTH SAN FRANCISCO
CA
94080
1
1
0
0
Chief Executive Officer
0
Common Stock
2023-08-16
4
S
0
5563
3.81
D
119437
D
Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 15, 2023.
Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $3.76 to $3.87. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Includes 109,375 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.
/s/ Jennifer Drimmer Rokovich, Attorney-in-Fact
2023-08-18